Back to Search
Start Over
Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
- Source :
- Oncology Research
- Publication Year :
- 2019
- Publisher :
- Cognizant Communication Corporation, 2019.
-
Abstract
- Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were 13.1 and 4.2 months, respectively. ORR and DCR were 21.8% and 60.3%, respectively. The survival time of patients who achieved partial response or stable disease was significantly superior to those with disease progression. Cox regression analysis showed that patients with M1c stage, subtype of cutaneous melanoma, or elevated LDH level (>upper limit of normal) had higher hazard ratios for overall survival. Our study, combined with those studies targeting patients with a c-Kit alteration, validates the role of imatinib as an important and promising therapeutic agent in the treatment of patients with advanced melanoma.
- Subjects :
- 0301 basic medicine
Oncology
Response rate
Male
Cancer Research
0302 clinical medicine
Stage (cooking)
Child
Melanoma
Aged, 80 and over
Hazard ratio
General Medicine
Middle Aged
Proto-Oncogene Proteins c-kit
Treatment Outcome
030220 oncology & carcinogenesis
Imatinib Mesylate
Female
medicine.drug
Adult
medicine.medical_specialty
Efficacy
Adolescent
c-Kit aberrations
Progression-free survival (PFS)
Antineoplastic Agents
Metastatic melanoma
Malignancy
Article
03 medical and health sciences
Young Adult
Internal medicine
medicine
Humans
neoplasms
Protein Kinase Inhibitors
Aged
Neoplasm Staging
Proportional Hazards Models
Retrospective Studies
Proportional hazards model
business.industry
Gene Amplification
Overall survival (OS)
Retrospective cohort study
Imatinib
medicine.disease
030104 developmental biology
Cutaneous melanoma
Mutation
business
Subjects
Details
- Language :
- English
- ISSN :
- 15553906 and 09650407
- Volume :
- 27
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Oncology Research
- Accession number :
- edsair.doi.dedup.....5d708e30fa5b75d9b1d133b19dc5dc74